An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease.
作者信息
Harrison Dawn S, Giang Jane, Darling Jama M
机构信息
Division of Gastroenterology and Hepatology University of North Carolina School of Medicine Chapel Hill NC.
Department of Pharmacy University of North Carolina Hospitals Chapel Hill NC.
出版信息
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):17-20. doi: 10.1002/cld.833. eCollection 2020 Jan.
Abstract
摘要
相似文献
1
An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease.格卡瑞韦、哌柏西利与秋水仙碱之间的相互作用导致一名慢性肾病患者发生横纹肌溶解症。
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):17-20. doi: 10.1002/cld.833. eCollection 2020 Jan.
2
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.在慢性 HCV 感染患者中，使用雷迪帕韦和奥比帕利联合应用酸抑制剂的疗效和药代动力学。
Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10.
3
Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.在体转运抑制研究向格拉替雷和哌仑他韦的临床药物相互作用的转化。
J Pharmacol Exp Ther. 2019 Aug;370(2):278-287. doi: 10.1124/jpet.119.256966. Epub 2019 Jun 5.
4
Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.在健康受试者中，他克莫司或环孢素与格卡瑞韦和哌仑他韦的药物相互作用。
Clin Pharmacol Drug Dev. 2019 Aug;8(6):779-789. doi: 10.1002/cpdd.671. Epub 2019 Mar 12.
5
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.真实世界中 glecaprevir/pibrentasvir 治疗慢性丙型肝炎感染的疗效和安全性：来自德国丙型肝炎注册研究的数据。
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.
6
Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.在肝移植后复发的丙型肝炎患者中，glecaprevir 和 pibrentasvir 治疗 8 或 12 周的疗效和安全性：一项日本多中心经验。
J Gastroenterol. 2019 Jul;54(7):660-666. doi: 10.1007/s00535-019-01561-1. Epub 2019 Feb 26.
7
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.在接受阿片类药物替代治疗的慢性丙型肝炎基因型 1-6 患者中，glecaprevir/pibrentasvir 的安全性和疗效。
Int J Drug Policy. 2019 Apr;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. Epub 2019 Feb 6.
8
Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.在血液透析患者中使用格卡瑞韦和哌柏西普清除丙型肝炎病毒的临床结局：一项多中心研究。
Hepatol Res. 2020 May;50(5):557-564. doi: 10.1111/hepr.13482. Epub 2020 Jan 27.
10
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.肝移植受者为 HCV 阴性而供者为 HCV 阳性时预先使用泛基因型直接作用抗病毒药物治疗：一项开放标签研究。
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):771-780. doi: 10.1016/S2468-1253(19)30240-7. Epub 2019 Jul 26.
引用本文的文献
1
Revolution in the diagnosis and management of hepatitis C virus infection in current era.当前时代丙型肝炎病毒感染诊断与管理的变革
World J Hepatol. 2022 Apr 27;14(4):647-669. doi: 10.4254/wjh.v14.i4.647.
本文引用的文献
1
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.格卡瑞韦和哌仑他韦治疗丙型肝炎病毒合并严重肾功能损害患者。
N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.
2
The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.接受直接作用抗病毒药物治疗的大多数丙型肝炎患者存在发生相关药物相互作用的风险。
United European Gastroenterol J. 2017 Aug;5(5):648-657. doi: 10.1177/2050640616678151. Epub 2016 Nov 4.
3
An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function.索磷布韦/来迪派韦与阿托伐他汀和秋水仙碱之间意外的相互作用导致一名肾功能受损患者发生横纹肌溶解症。
Case Rep Med. 2016;2016:3191089. doi: 10.1155/2016/3191089. Epub 2016 Aug 22.
4
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.格拉瑞韦联合艾尔巴韦在初治和经治的丙型肝炎病毒基因型 1 感染和 4-5 期慢性肾脏病患者中的疗效（C-SURFER 研究）：一项联合 III 期研究。
Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5.
5
Rhabdomyolysis.横纹肌溶解症。
Chest. 2013 Sep;144(3):1058-1065. doi: 10.1378/chest.12-2016.
6
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.多国循证推荐意见：痛风的诊断与管理——3e 倡议中广泛的风湿病学家专家组对系统文献回顾和专家意见的整合。
Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325. Epub 2013 Jul 18.
7
Fibroscan (transient elastography) for the measurement of liver fibrosis.用于测量肝纤维化的Fibroscan（瞬时弹性成像）。
Gastroenterol Hepatol (N Y). 2012 Sep;8(9):605-7.
8
Economic model of a birth cohort screening program for hepatitis C virus.基于队列的丙型肝炎病毒筛查计划的经济模型。
Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.
9
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.美国初级保健环境中基于出生队列的丙型肝炎抗体筛查的成本效益分析。
Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.
10
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.美国丙型肝炎病毒 (HCV) 感染者的老龄化：HCV 流行率和疾病进展的多队列模型。
Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6. doi: 10.1053/j.gastro.2009.09.067. Epub 2009 Oct 25.
Zotero 插件